A low-dose supplement from chicken cartilage thought to calm gut immune activity against joint cartilage. The most consistent evidence shows modest relief of knee pain, stiffness, and reduced function, plus better joint comfort and flexibility in active adults. Cartilage protection and broader effects remain unproven. Safety looks reassuring, but studies are small, short, and often industry-funded. (Full Review)

Protocol

Dose & Form

40 mg once daily

Single standardized capsule (~10 mg active collagen); low fixed dose, more is not better

Timing

Empty stomach

Commonly at bedtime or 30–60 minutes before a meal

Consistency

Daily, 8–12+ weeks

Uninterrupted daily use; effect is cumulative, not acute

Time to effect

Knee osteoarthritis relief

3–6 months

Peak pain, stiffness & function improvement

Active-adult joint comfort

12–24 weeks

Range of motion & pain-free exertion gains

Initial onset

4–12 weeks

Gradual emergence; allow an 8–12 week trial before judging

Benefits

High: Knee osteoarthritis symptom relief

Medium: Activity-related joint discomfort and flexibility in healthy adults

Low: Rheumatoid arthritis symptom modulation

Speculative: Chondroprotection and cartilage preservation; systemic immune and inflammatory modulation

Contraindications

Known chicken/poultry protein allergy

Pregnancy or breastfeeding

Active autoimmune disease or immunosuppressive therapy (clinician oversight only)

Key Interactions

Immune-modifying drugs (methotrexate, corticosteroids, biologics)

NSAIDs (ibuprofen, naproxen)

Other joint supplements (glucosamine, chondroitin, MSM, boswellia, hydrolyzed collagen)

Risk & Side Effects

Medium: Mild gastrointestinal discomfort

Low: Allergic or hypersensitivity reactions; headache and nonspecific adverse events

Speculative: Theoretical immune dysregulation; unknown long-term safety

Monitoring

Marker	Target	Why
hs-CRP	< 1.0 mg/L	Tracks systemic inflammation that may accompany joint disease
ESR	< 15–20 mm/hr	Secondary inflammation marker; mainly relevant if autoimmune joint disease is suspected
WOMAC / symptom score	Improvement vs personal baseline	Quantifies pain, stiffness, and function over time

Cadence: Reassess symptoms and function at ~4 weeks, 8–12 weeks, then every 3–6 months; repeat optional inflammatory markers at 3–6 month intervals only if elevated at baseline

Qualitative Assessment

Reduced day-to-day joint pain and morning stiffness
Greater ease and range of motion in affected joints
Longer or more comfortable exercise sessions before discomfort appears
Reduced reliance on as-needed pain relievers
Improved confidence in mobility and daily function

Undenatured Type II Collagen for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment